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Abstract
Background: The CD44 cell adhesion molecule is aberrantly expressed in many breast tumors and has been
implicated in the metastatic process as well as in the putative cancer stem cell (CSC) compartment. We aimed to
investigate potential associations between alternatively spliced isoforms of CD44 and CSCs as well as to various
breast cancer biomarkers and molecular subtypes.
Methods: We used q-RT-PCR and exon-exon spanning assays to analyze the expression of four alternatively spliced
CD44 isoforms as well as the total expression of CD44 in 187 breast tumors and 13 cell lines. ALDH1 protein
expression was determined by IHC on TMA.
Results: Breast cancer cell lines showed a heterogeneous expression pattern of the CD44 isoforms, which shifted
considerably when cells were grown as mammospheres. Tumors characterized as positive for the CD44
+/CD24
-
phenotype by immunohistochemistry were associated to all isoforms except the CD44 standard (CD44S) isoform,
which lacks all variant exons. Conversely, tumors with strong expression of the CSC marker ALDH1 had elevated
expression of CD44S. A high expression of the CD44v2-v10 isoform, which retain all variant exons, was correlated
to positive steroid receptor status, low proliferation and luminal A subtype. The CD44v3-v10 isoform showed similar
correlations, while high expression of CD44v8-v10 was correlated to positive EGFR, negative/low HER2 status and
basal-like subtype. High expression of CD44S was associated with strong HER2 staining and also a subgroup of
basal-like tumors. Unsupervised hierarchical cluster analysis of CD44 isoform expression data divided tumors into
four main clusters, which showed significant correlations to molecular subtypes and differences in 10-year overall
survival.
Conclusions: We demonstrate that individual CD44 isoforms can be associated to different breast cancer subtypes
and clinical markers such as HER2, ER and PgR, which suggests involvement of CD44 splice variants in specific
oncogenic signaling pathways. Efforts to link CD44 to CSCs and tumor progression should consider the expression
of various CD44 isoforms.
Background
Breast cancer is characterized by a remarkable biological
heterogeneity both between and within tumors. Breast
tumors can be stratified into molecular subtypes using
gene expression profiling [1-3] and within a tumor, a
variety of cell populations with different phenotypes can
be found. Earlier studies have identified a subpopulation
of putative cancer stem cells (CSCs) with the phenotype
CD44
+/CD24
-/low [4] and more recently, aldehyde dehy-
drogenase (ALDH) activity was shown to mark normal
as well as malignant mammary stem cells [5]. These
CSCs have been associated with enhanced invasive
properties [6], increased resistance to radio- and che-
motherapy [7,8], as well as poorer prognosis [5,9]. Pre-
sence of CD44
+/CD24
- tumor cells has also been
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any medium, provided the original work is properly cited.associated with the aggressive basal-like molecular sub-
type of breast cancer [10].
CD44 is a transmembrane glycoprotein that partici-
pates in many cellular processes including regulation of
cell division, survival, migration, and adhesion [11]
through the binding of its major ligand, hyaluronic acid,
and by acting as a cellular platform for growth factors
and heparan-sulphate proteoglycans. It can also act as a
co-receptor to mediate signaling of the HER family and
MET receptor tyrosine kinases, possibly by organizing
the assembly of functional complexes [12,13]. CD44 also
provides a link between the plasma membrane and the
actin cytoskeleton, modulating cellular shape and moti-
lity [12,13]. The human CD44 gene is located on chro-
mosome 11p13 and consists of 19 coding exons of
which 9, residing between constitutive exons 5 and 6,
can be alternatively spliced into many different isoforms
with tissue and differentiation-specific expression [12].
The standard isoform of CD44 (CD44S) contains none
of the 9 variable exons, whereas the CD44v2-v10 iso-
form includes them all (exon v1 is not expressed in
humans). The CD44v3-v10 isoform has one less exon
and the CD44v8-v10 isoform includes only the last
three of the variable exons. Additional isoforms formed
by alternative splicing, and various posttranslational
modifications further increase the heterogeneity of the
CD44 protein products [12].
The CD44 molecule consists of an amino-terminal
extracellular and ligand-binding domain, a membrane-
proximal stem loop including the variable region, a
transmembrane region, and a cytoplasmic tail that
attaches to actin and ankyrin in the cytoskeleton [12].
The epitope recognized by the CD44 antibodies (clones
156-3C11 and G44-26) commonly used for isolation of
CSCs is situated in the amino-terminal region of CD44
consisting of the nonvariable exons 1 to 5, indicating
that all CD44 isoforms should be detected by this anti-
body [13]. Different isoforms of CD44 have been
described to be involved in metastatic spread in different
tumor forms even if the results are contradictory
[14,15]. However, it has not been shown if the expres-
sion of specific CD44 isoforms is associated with CSCs
or various breast cancer biomarkers and tumor sub-
types. In order to investigate this further we analyzed
the four CD44 isoforms described above using quantita-
tive real-time PCR (q-RT-PCR) in a large material of
breast tumors and cell lines.
Methods
Cell lines
The breast cell lines BT-474, HCC1428, HCC1937,
MCF7, MCF10A, MDA-MB-231, MDA-MB-361, MDA-
MB-436, SK-BR-3 and ZR-75-1 were obtained from
American Type Culture Collection (ATCC, Mannanas,
VA). JIMT-1 was purchased from the German Collec-
tion of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). L56Br-C1 was established at
the Department of Oncology, Lund University [16] and
PMC42 [17] was received through a generous gift from
Dr. Anna Git at the Breast Cancer Functional Genomics
Laboratory, Cancer Research UK, Cambridge Research
Institute and Department of Oncology, University of
Cambridge, UK. The HCC1937, MDA-MB-436, and
L56Br-C1 cell lines are from BRCA1 germline mutation
carriers [16].
Cell culture
All cell lines were cultured under adherent conditions in
RPMI1640 (Invitrogen, Carlsbad, CA) supplemented
with 1 mM Na-puruvate, non-essential amino acids, 50
U/ml penicillin, 50 ng/ml streptomycin (all from Invitro-
gen) and 10% fetal bovine serum (FBS, Hyclone, Logan,
UT). MDA-MB-361 was cultured as above except for
20% concentration of FBS. MCF7, BT-474, MDA-MB-
436 and L56Br-C1 were additionally supplemented with
10 μg/ml insulin (Invitrogen). HCC1937 was supplemen-
ted with 10 μg/ml insulin and 20 ng/ml epidermal
growth factor (EGF, Invitrogen). MCF10A was supple-
mented with 10 μg/ml of insulin, 20 ng/ml EGF, 100
ng/ml cholera toxin (Sigma, St. Louis, CO) and 500 ng/
ml hydrocortisone (Sigma). To enrich for stem cell
properties, cells were also cultured as non-adherent
multicellular spheres (mammospheres) in Mammary
Epithelial Growth Medium (Cambrex, Walkersville)
including hydrocortisone, insulin and GA-1000) [18].
The media was additionally supplemented with 20 ng/
ml of EGF, 20 ng/ml basic fibroblast growth factor
(R&D Systems, Minneapolis, MN) and B27 (Invitrogen).
Mammospheres were passaged once a week by enzy-
matic dissociation with Accutase (Innovative Cell Tech-
nologies, Inc., San Diego, CA) followed by mechanical
dissociation by pipetting.
Patients and tumors
Fresh frozen tumor tissue from 151 patients diagnosed
with stage II primary breast cancer were obtained from
the Southern Sweden Breast Cancer Group’s tissue bank
at the Department of Oncology, Lund University. These
patients were treated with 2 or 5 years of adjuvant
tamoxifen and were included in two previous rando-
mized trials [19,20]. Included in the study were also 36
tumors from patients with germline BRCA1 or BRCA2
mutations (32 and 4 tumors, respectively). The tissue
microarray used has been described earlier [10]. The
study was approved by the regional ethical committee at
Lund University (reg. no. LU240-01 and 2009/658),
waiving the requirement for informed consent for the
study.
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Estrogen (ER) and progesterone receptor (PgR) status
and S-phase fraction were obtained earlier from enzyme
immunoassay and DNA flow cytometry, respectively
[19,21]. Immunohistochemistry (IHC) on tissue microar-
rays (TMAs) was also previously used for staining of
epidermal growth factor receptor (EGFR) (n = 69
tumors) and human epidermal growth factor receptor 2
(HER2) (n = 82 tumors) protein [22,23], and for double-
staining of CD44 (Clone 156-3C11) and CD24 protein
(n = 80) [10]. The proportion of CD44
+,C D 2 4
+ and
CD44
+/CD24
- tumor cells was used in scoring: 0 = 0%
positive tumor cells, 1 = 1-10% positive cells, 2 = 11-
50% positive cells, 3 = 51-75% positive cells, 4 = 76-
100% positive cells. PTEN protein expression and
PIK3CA mutational status were available for 110 and
107 of the tumors, respectively [24]. Microarray gene
expression data was available for 157 of the tumors
[25-27] and tumors were subclassified according to Hu
et al. [3] as described [10]. Samples with Pearson corre-
lation < 0.2 to all centroids were considered unclassified.
ALDH1 expression
ALDH1 protein expression was determined by IHC on
TMA. Antigen retrieval was achieved by placing the
slides in citrate buffer (Dako S1699) (DAKO, Glostrup,
Denmark) at 125°C in a 2100 Retriever (PickCell
Laboratories, Amsterdam, the Netherlands) for 5 min-
utes and ALDH1 was detected with a mouse monoclo-
n a lp r i m a r ya n t i b o d y( C l o n e4 4 ,B DB i o s c i e n c e s ,S a n
Jose, CA, USA) followed by EnVision™ on an Autostai-
ner (DAKO). Cytoplasmic staining was recorded as
negative (< 1% positive tumor cells), weakly or strongly
positive. In total 210 breast tumors were analyzed, of
which 73 were also analyzed for CD44 isoforms.
Flow cytometric analysis of CD44 and CD24
Cells were washed once with phosphate-buffered saline
and harvested using Accutase. Detached cells were
labeled with fluorochrome-conjugated monoclonal anti-
bodies obtained from BD Biosciences Pharmingen (San
Diego, CA) against human CD44 (FITC; clone G44-26)
and human CD24 (PE; clone ML5). Appropriate isotype
controls were used to set the threshold for CD44 and
CD24 positive cells. The labeled cells were analyzed on
a FACSCalibur (BD Biosciences). Dead cells were
excluded by staining with 7-aminoactinomycin D
(Sigma-Aldrich, St. Louis, MO).
RNA extraction
Approximately 100 mg of frozen tumor material was
pulverized using a microdismembrator immediately fol-
lowed by homogenization in Trizol reagent (Invitrogen,
Carlsbad, CA) and total RNA was isolated according to
manufacturer’s instructions. A second round of purifica-
tion was performed using the RNeasy kit (Qiagen, Hil-
den, Germany) according to manufacturer’s instructions.
The total RNA from breast cell lines was extracted
using the RNeasy kit. The concentration of total RNA
was measured by a ND-1000 NanoDrop spectrophot-
ometer (NanoDrop Technologies, Wilmington, DE) and
integrity of RNA was verified using the 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA).
Gene expression analysis of cell lines
350 ng RNA per sample was amplified and biotinylated
using Illumina TotalPrep 96 RNA Amplification Kit
(Ambion, Austin, TX). 750 ng cRNA per sample was
hybridized to Illumina Human-12 v3 Expression Bead
Chip (Illumina, San Diego, CA) using Whole-Genome
Expression Direct Hybridisation kit (Illumina) and
scanned with the Illumina BeadArray reader according
to manufacturer’s instructions. The mean signal of the
data was uploaded to BASE2 [28]. The data was quantile
normalized in BASE2 and then exported into MeV [29].
Log2 transformation and median center was performed
across genes. Gene expression data was available for a
panel of 24 cell lines including all 13 cell lines selected
for q-RT-PCR analysis. Like Neve et al. [30] we discov-
ered 3 groups when performing hierarchical clustering
based on the most varying genes and we also assigned
cell lines to luminal, basal A or basal B. 21 of our 24
cell lines were included in Neve et al. and we obtained a
similar clustering pattern using our data [30].
Quantitative real-time PCR
Different mRNA transcripts of CD44 were obtained
from The National Center for Biotechnology Informa-
tion (NCBI) Reference Sequence (RefSeq) database.
Inventoried exon-exon spanning TaqMan gene expres-
sion assays (Applied Biosystems, Foster City, CA) were
used for detection of CD44; Hs00153304_m1 (CD44
total, NM_001001389.1, NM_001001390.1,
NM_001001391.1, NM_001001392.1, NM_000610.3),
Hs01081480_m1 (CD44v3-v10, NM_001001389.1),
Hs01081475_m1 (CD44v8-v10, NM_001001390.1),
Hs01081473_m1 (CD44S, NM_001001391.1) and
Hs01075866_m1 (CD44v2-v10, NM_000610.3). The
RefSeqs; NM_001202555.1, NM_001202556.1,
NM_001202557.1 recently added to the NCBI database
were not included in our study. Three different endo-
genous controls were used: GAPDH (4333764T), ACTB
(Hs99999903_m1), and PUM1 (Hs00206469_m1)
(Applied Biosystems). TaqMan Gene Expression Master
Mix (Applied Biosystems) was used and all reactions
were run in triplicates. A CAS1200 instrument and a
Rotor-Gene instrument (Corbett Life Science, Sydney,
Australia) was used for automated PCR setup of the q-
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used for calculations of average Ct-values for each sam-
p l ea n dt h ed a t aw a se x p o r t e dt oM i c r o s o f tE x c e lf o r
further analysis. The average Ct-value for all three endo-
genous controls was calculated for each sample. To cal-
culate the relative expression of the CD44 transcripts
detected by each gene expression assay in respective
sample the delta-delta Ct-method was used [31]. Either
one of the analyzed tumors or cell lines were arbitrarily
set as a calibrator. The calculated relative expression
values were log2-transformed.
Western blot
Cells were lysed in RIPA buffer containing protease
inhibitor (Roche, Basel, Swizerland) and mixed with 2×
NuPage sample buffer. Samples were run on Bis Tris
NuPage Gel 4-12% and then transferred to PVDF mem-
branes (Invitrogen). Membranes were blocked with 5%
non-fat dry-milk in Tris-buffered saline with 0.1%
Tween (TBST) overnight at 4°C. Membranes were incu-
bated with CD44 antibody (Clone 156-3C11) for 2
hours at RT followed by horse-radish-peroxidase conju-
gated goat anti-rabbit IgG (GE Healthcare, Chalfont, St.
Giles, UK) for 1 hour at RT in 5% dry-milk with TBST.
Visualization was performed using ECL Plus (GE
Healthcare).
Statistical analysis
Spearman correlation coefficient was used to assess the
association between two continuous variables, Mann-
Whitney test was used for two-group comparisons of
continuous variables and Kruskal-Wallis test was used
to compare expression of continuous variables in multi-
ple subgroups. Fisher’se x a c tt e s tw a su s e dt oa n a l y z e
contingency tables. Cox regression analysis was used for
analysis of time-to-event data and Kaplan-Meier plots to
illustrate the results. Schoenfeld’s test was used to test
proportional hazards assumptions. All statistical analyses
were carried out in Stata 10.0 (StataCorp LP, College
Station, TX). All tests were two-sided and P-values <
0.05 were considered as significant.
Cluster analysis
Hierarchical clustering using Pearson correlation with
average linkage was performed in MeV 4.6.1 [29]. Log2
ratios were adjusted by median centering of samples fol-
lowed by median centering of genes before clustering.
Results
Correlation between CD44 mRNA and protein expression
in breast cell lines
To investigate the presence of different CD44 splice var-
iants in breast cell lines we analyzed 13 cell lines by q-RT-
PCR. The cell lines were assigned to luminal, basal A or
basal B according to Neve et al [30]. The total expression
of CD44 transcripts was first compared to flow cytometry
data of CD44 and a relatively good agreement between
mRNA and protein expression could be seen. However,
the MDA-MB-361 cell line has 79.6% of CD44 positive
c e l l sd e s p i t eam o d e r a t ee x p r e s s i o nl e v e lo ft o t a lC D 4 4
(Table 1). Possibly, the relatively high amount of synthe-
sized CD44 protein in MDA-MB-361 can be explained by
for example post-transcriptional modifications and trans-
lational regulation specific only for this cell line. Exon-
exon spanning q-RT-PCR assays were further used to
illustrate a very heterogeneous expression pattern of differ-
ent alternatively spliced CD44 transcripts (Figure 1). In
general, the basal A and B cell lines showed a much higher
total expression of CD44 than the luminal cell lines. We
also found that basal A and basal B cell lines had almost
mutually exclusive expression of different CD44 tran-
scripts. For instance, the MDA-MB-231 and HCC1937
cells had similar total CD44 protein and RNA expression
levels, however, while this was primarily due to expression
of CD44S in the former cells, this isoform was virtually
undetectable in the latter cells. Of interest, PMC42 cells,
described as having stem cell-like properties [17], showed
exclusive expression of the CD44S isoform.
Altered expression of CD44 isoforms in mammosphere
cultures
Four of the breast cancer cell lines (MDA-MB-231,
MCF7, JIMT-1 and L56Br-C1) could be readily cultured
Table 1 Comparison of the proportion of CD44+ cells as
determined by flow cytometry to the relative mRNA
expression determined by q-RT-PCR
Cell line CD44+ by FCM (%
positive cells)
1
Relative mRNA expression
of total CD44
MCF7 15.1 1.00
MDA-MB-
361
79.6 0.95
BT-474 0 0.09
ZR-75-1 6.00 0.39
SK-BR-3 7.42 0.04
HCC1428 65.8 8.96
MDA-MB-
436
97.3 9.37
L56Br-C1 49.5 2.04
MDA-MB-
231
99.2 9.35
HCC1937 96.0 9.18
PMC42 98.4 3.89
JIMT-1 99.8 17.4
MCF10A 99.7 6.21
The relative mRNA expression was calculated using the cell line MCF7 as
reference.
1 Appropriate isotype control was used to set the threshold for CD44 positive
cells.
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Page 4 of 13under conditions where they form non-adherent mam-
mospheres, a state thought to enrich for stem cell-like
features [18]. Flow cytometric analysis showed that the
proportion of CD44
+/CD24
- cells in MDA-MB-231 was
very high (> 95%) in both monolayer and non-adherent
cultures while in MCF7 there was no clear increase in
the initially very low CD44
+/CD24
- cell proportion (<
0.3%). The CD44
+/CD24
- proportion of JIMT-1 and
L56Br-C1 cells increased from 45.5% to 82.6% and 1.2%
to 7.2%, respectively, when grown as mammospheres
compared to monolayers.
We found considerable and variable changes in the
expression of CD44 isoforms during these experiments
(Figure 2A). Expression of CD44S decreased in three of
four cell lines, the CD44v3-v10 isoform was upregulated
in all four cell lines investigated and the expression of
CD44v2-v10 and CD44v8-v10 were higher in mammo-
spheres as compared to adherent cultures for three of
four cell lines. For instance, MDA-MB-231 cells drama-
tically decreased their expression of CD44S and
increased CD44v2-v10 and CD44v3-v10 expression,
while the L56Br-C1 cells showed the opposite pattern.
Changes in the pattern of different CD44 protein var-
iants were also indicated by Western blot for JIMT-1
(clone 156-3C11) (Figure 2B).
CD44 isoforms correlate to CSC biomarkers in primary
breast tumors
RNA expression of CD44 isoforms was investigated in a
set of 187 primary breast tumors. As shown in Table 2,
the CD44v3-v10 isoform was most strongly associated
to the total CD44 mRNA expression, while CD44S
showed the lowest correlation. A subset of these tumors
has previously [10] been stained for CD44 (and CD24)
by IHC. When comparing CD44 RNA and protein
expression we found that all analyzed isoforms except
CD44S were positively correlated to the protein level of
CD44 (Table 2). Similar results were obtained when
CD44 RNA expression levels were compared with the
presence of cells with the putative cancer stem cell phe-
notype CD44
+/CD24
- (Table 3).
We further analyzed the correlation of CD44 isoforms
to expression of ALDH1, another suggested marker of
normal and malignant stem cells [5]. ALDH1 staining
was detected in 31% of all 210 tumors, with a strong
staining in 9%. Strong ALDH1 staining was significantly
associated with negative ER (P = 0.008) and PgR status (P
= 0.015), strong HER2 expression (P = 0.025) and with a
high S-phase fraction (P = 0.005). ALDH1 status did not
correlate with presence of CD44
+/CD24
- tumor cells. We
had overlapping ALDH1 IHC and CD44 q-RT-PCR data
for 73 tumors, 12 (16%) of which were strongly ALDH1
positive. Surprisingly, expression of CD44S was positively
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Figure 1 CD44 splice variants show heterogeneous expression
patterns in breast cell lines. A to E. Q-RT-PCR analyses (on mRNA
level) of the splice variants CD44v2-v10, CD44v3-v10, CD44v8-v10
and CD44S in breast cell lines of different molecular subtypes. The
expression of CD44S was generally high in the basal B cell lines
whereas the other isoforms were predominately expressed in the
basal A cell lines.
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Page 5 of 13associated to ALDH1+ tumors (Table 3). This was con-
firmed by microarray ALDH1 expression data, which
showed correlation to CD44S (Spearman r = 0.49, P <
0.00001; n = 131) but not to other CD44 isoforms or
total CD44 RNA expression (Figure 3A-B).
Correlation of CD44 isoforms to different clinical
biomarkers in tumors
The expression of different CD44 isoforms was signifi-
cantly associated to certain patient and tumor character-
istics (Table 4). A high expression of CD44v2-v10 was
correlated to positive ER and PgR status, low S-phase
fraction and postmenopausal age. High expression of
CD44v3-v10 correlated to positive steroid receptor sta-
tus and low proliferation, but also to negative/low HER2
status. Strong EGFR expression and negative/low HER2
status were correlated to expression of CD44v8-v10 but
showed no association to steroid receptor status or pro-
liferation rate. Interestingly, a correlation was found
between the expression of CD44S and strong HER2
expression, as well as to smaller tumor size. Lymph
node status could not be associated to any of the iso-
forms. We found a correlation of CD44v2-v10 expres-
sion to the presence of PIK3CA mutations. However,
none of the CD44 isoforms were associated to PTEN
status. 10-year overall survival was significantly better
for patients with tumors showing high expression of
CD44v2-v10 (HR = 0.64, 95% CI = 0.27-1.21, P = 0.007).
Distinct expression of CD44 isoforms in tumors of
different molecular subtype
Gene expression microarray data was used to classify
tumors into subtypes according to Hu et al. [3]. A Pear-
son correlation ≥ 0.2 to at least one of the five subtype
gene expression centroids was found in 145 tumors,
while the remaining tumors was considered as unclassi-
fied and excluded from further analysis. As expected
from their predominant expression in ER/PgR positive
and less proliferating tumors, the CD44v2-v10 and
CD44v3-v10 isoforms were associated to the luminal A
subtype and were expressed to lesser degree in basal-
like tumors (Figure 4A-B). Specifically, CD44v2-v10
expression was significantly higher in luminal A com-
pared to the basal-like (P = 0.0001), luminal B (P =
0.038), normal-like (P = 0.011) and HER2-enriched sub-
type (borderline significance; P = 0.051). A similar pat-
tern was seen for CD44v3-v10 with higher expression in
luminal A tumors compared to basal-like (P < 0.001),
luminal B (P < 0.001), normal-like (P = 0.003) and
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Figure 2 Mammosphere propagation of cell lines changed the mRNA and protein expression of CD44 isoforms.A .B r e a s tc a n c e rc e l l
lines grown as monolayer cells or mammospheres were analyzed for mRNA expression of CD44 isoforms using q-RT-PCR. In general, the gene
expression of the alternatively spliced variants CD44v2-v10, CD44v3-v10, CD44v8-v10 increased and the expression of CD44S decreased for cells
cultured as mammospheres. B. Western blot analysis (CD44 antibody, clone 156-3C11) of the breast cancer cell line JIMT-1 confirmed changes in
expression of CD44 variants for cells propagated as mammospheres.
Table 2 Correlations of the mRNA expression of different
CD44 splice variants to total CD44 mRNA and protein
expression as determined by q-RT-PCR and IHC
respectively
Splice variant CD44 total mRNA
expression
(n = 187)
CD44 protein
expression
(n = 80)
r
1 P-value r
1 P-value
CD44v2-v10 0.58 < 0.00001 0.25 0.026
CD44v3-v10 0.72 < 0.00001 0.34 0.002
CD44v8-v10 0.64 < 0.00001 0.36 0.001
CD44S 0.26 0.001 -0.20 0.070
CD44 total - - 0.37 0.001
1Spearman’s correlation coefficient (rho)
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Page 6 of 13HER2-enriched subtype tumors (P = 0.001). A different
pattern was seen for CD44v8-v10, with highest expres-
sion in normal-like and basal-like tumors and lowest
expression in luminal B (P = 0.018, as compared to nor-
mal-like) and HER2-enriched (P = 0.019) classified
tumors (Figure 4C). The expression of CD44S varied
less between subtypes but, as expected, showed highest
median expression in the HER2-enriched subtype, being
significant when comparing to luminal A tumors (P =
0.050) (Figure 4D). The total expression of CD44 was
significantly higher in the luminal A subgroup compared
to basal-like (P = 0.007), luminal B (P = 0.009) and
HER2-enriched (P = 0.002) classified tumors while the
normal-like subgroup showed borderline significance (P
= 0.051) (Figure 4E).
The basal-like subtype showed a better 10-year overall
survival for tumors with high expression of total CD44
(HR = 0.22, 95% CI = 0.06 to 0.79, P = 0.021) as well as
CD44v2-v10, CD44v3-v10, CD44v8-v10 (HR = 0.44, 95%
CI = 0.24 to 0.81, P = 0.008; HR = 0.29, 95% CI 0.14 to
0.61, P = 0.001; HR = 0.41, 95% CI 0.18 to 0.90, P =
0.026, respectively). Similar to basal-like tumors the
luminal A subtype showed a better survival at high
expression of total CD44 (HR = 0.20, 95% CI = 0.05 to
0.93, P = 0.04).
Patterns of CD44 isoform expression in relation to
biomarkers and survival
The expression levels of CD44 isoforms were used in
hierarchical clustering to subdivide the 187 tumors into
four main clusters (Cluster A-D; Figure 5). Strikingly,
while Cluster A had high CD44v2-v10 and low
CD44v8-v10 expression, the opposite pattern was seen
in Cluster D. Furthermore, Cluster B tumors showed
high expression of CD44v2-v10, CD44v3-v10 and low
expression of CD44S while the reverse expression pat-
tern was observed in Cluster C. The four clusters were
significantly correlated to various biomarkers (Table 5)
and to 10-year overall survival (log rank P = 0.05) (Fig-
ure 6). Cluster B tumors were associated with best over-
all survival and was characterized by mostly ER and PgR
positive status, negative/low HER2 status, low prolifera-
tion and luminal A subtype, but also by higher PIK3CA
mutation frequency. Cluster A tumors were mostly ER
and PgR positive, but also more often strongly HER2
positive and of luminal B or HER2-enriched subtypes,
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Table 3 Associations between the mRNA expression of CD44 isoforms and the cancer stem cell phenotypes CD44
+/CD24
- and ALDH1
+ (as determined by IHC)
Splice variant CD44+/CD24- ALDH1+
All
2
n=8 0
Negative
2
n = 51 (64%)
Positive
2
n = 29 (36%)
P
1 All
2
n=7 3
Neg/Weak
2
n = 61(84%)
Strong
2
n = 12 (16%)
P
1
CD44v2-v10 1.650 1.580 1.843 0.045 1.594 1.594 1.706 0.69
CD44v3-v10 1.231 1.124 1.380 0.002 1.188 1.224 1.131 0.92
CD44v8-v10 1.440 1.115 1.640 0.0007 1.457 1.457 1.387 0.81
CD44S 0.257 0.293 0.214 0.024 0.261 0.240 0.467 0.011
CD44 total 0.702 0.628 0.818 0.002 0.699 0.629 0.763 0.24
1 Mann-Whitney test
2 Median values
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Page 7 of 13as well as diagnosed at higher age. Cluster A showed a
slightly worse prognosis compared to Cluster B (P =
0.17, HR = 1.7, 95% CI: 0.8 to 3.6). Clusters C and D
showed enrichment for the basal-like subtype and were
associated to higher proliferation (Figure 5), although
Cluster C included tumors with high CD44S expression
and of luminal B and HER2-enriched subtype. Cluster
D was enriched for tumors of both basal- and normal-
like subtypes characterized by high CD44v8-v10 and
low CD44S expression. Both Cluster C and Cluster D
showed significantly worse prognosis compared to Clus-
t e rB( P=0 . 0 2 ,H R=2 . 2 ,9 5 %C I=1 . 1t o4 . 2 ;P=
0.01, HR = 2.4, 95% CI = 1.2 to 4.6, respectively). Three
tumors with high CD44 gene and 11p13 amplification
were all assigned to cluster D and they all had a high
expression of v8-v10. Presence of tumors with the
CD44
+/CD24
- phenotype varied significantly (P = 0.01),
being more common in Cluster B and D (Figure 5).
ALDH1+ status was found in all clusters, but less com-
mon in Cluster D. Multivariate survival analysis
adjusted for age, node status and tumor size showed
significantly worse outcome for Cluster C and D com-
pared to Cluster B (HR = 2.1, 95% CI = 1.1 to 4.3, P =
0.03 respective HR = 2.1, 95% CI = 1.1 to 4.4, P =
0.04), respectively, but no significant difference between
Cluster A and Cluster B.
Table 4 Comparisons of the CD44 isoform mRNA levels in tumors of different clinical characteristics
n (%) CD44
v2-v10
2
P
1 CD44
v3-v10
2
P
1 CD44
v8-v10
2
P
1 CD44
standard
2
P
1 CD44
total
2
P
1
Age 180 1.645 1.276 1.340 0.295 0.736
< 50 years 47 (26) 1.432 0.0063 1.228 0.23 1.615 0.12 0.250 0.32 0.732 0.42
≥50 years 133 (74) 1.733 1.281 1.301 0.311 0.749
Tumor size 167 1.664 1.257 1.303 0.294 0.734
≤20 mm 46 (28) 1.791 0.22 1.311 0.48 1.547 0.41 0.398 0.0027 0.802 0.071
> 20 mm 121 (72) 1.638 1.248 1.258 0.271 0.720
Lymph node status 166 1.666 1.264 1.308 0.295 0.734
Negative (n = 0) 52 (31) 1.591 0.25 1.221 0.65 1.349 0.060 0.273 0.14 0.740 0.96
Positive (n > 0) 114 (69) 1.727 1.287 1.276 0.321 0.732
S-phase fraction 119 1.682 1.281 1.354 0.281 0.745
Low (< 12%) 75 (63) 1.859 0.0001 1.347 0.0021 1.322 0.86 0.283 0.92 0.802 0.0014
High (≥12%) 44 (37) 1.404 1.163 1.368 0.265 0.621
ER 180 1.650 1.243 1.322 0.300 0.736
Negative (< 25 fmol/mg) 86 (48) 1.461 0.0020 1.142 0.0018 1.440 0.32 0.309 0.53 0.706 0.086
Positive (≥25 fmol/mg) 94 (52) 1.834 1.361 1.272 0.288 0.767
PgR 178 1.601 1.243 1.323 0.297 0.736
Negative (< 25 fmol/mg) 107 (60) 1.562 0.0024 1.151 0.0007 1.355 0.87 0.299 0.53 0.723 0.17
Positive (≥25 fmol/mg) 71 (40) 1.875 1.461 1.303 0.293 0.771
HER2 82 1.716 1.231 1.343 0.257 0.708
Weak/negative 63 (77) 1.759 0.26 1.290 0.022 1.544 0.014 0.230 0.0016 0.737 0.054
Strong (score = 3) 19 (23) 1.594 1.139 1.115 0.442 0.682
EGFR 69 1.664 1.237 1.312 0.254 0.712
Weak/negative 58 (84) 1.686 0.97 1.236 0.56 1.284 0.032 0.257 0.34 0.708 0.43
Strong (score≥7) 11 (16) 1.580 1.237 1.734 0.202 0.818
PTEN 110 1.675 1.276 1.347 0.269 0.730
Negative 34 (31) 1.586 0.22 1.182 0.18 1.337 0.98 0.309 0.16 0.692 0.34
Positive 76 (69) 1.727 1.322 1.347 0.241 0.739
PIK3CA 107 1.669 1.270 1.312 0.271 0.715
Wildtype 76 (71) 1.589 0.0036 1.233 0.075 1.398 0.15 0.281 0.78 0.714 0.40
Mutation 31 (29) 1.965 1.355 1.178 0.249 0.752
Distant metastasis 149 1.733 1.287 1.292 0.293 0.744
Negative 99 (66) 1.837 0.12 1.328 0.15 1.292 0.73 0.284 0.52 0.752 0.27
Positive 50 (33) 1.618 1.199 1.294 0.304 0.726
1 Mann-Whitney test
2 Median values
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T h eC D 4 4m o l e c u l ea n ds e v e r a lo fi t si s o f o r m sh a v e
attained a lot of focus during the last decades, being
described as aberrantly expressed in cancer cells and
involved in metastatic spread in various tumor forms
[12]. However, survival data coupled to expression of
CD44 isoforms have often given rise to contradictory
results [14,15]. Possibly this may be due to poor specifi-
city of different CD44 antibodies, but also to small sam-
ple numbers and biased selection, particularly in breast
cancer which is a heterogeneous disease consisting of
several subtypes with different biology and clinical out-
come [2]. The interest for CD44 was reinforced by the
finding that tumorigenicity of breast cancer cells was
limited to a putative CSC subpopulation with CD44
+/CD24
-/low expression [4]. Moreover, the CD44
+/CD24
-
phenotype was found to correlate with the more aggres-
sive basal-like subtype of breast cancer [10]. While the
concept of CSCs is still under debate and the establish-
ment of relevant assays and markers to describe their
identity ongoing, this is clearly a clinically important
subject where drugs that selectively target and kill the
core of tumors are being developed [32,33].
Here we present data to suggest that the analysis and
study of CD44 expression in cancer development should
take the presence of various isoforms into account.
Since the antibody used in most previous studies for
selection of CSC properties recognizes an epitope
located in a non-variable region of CD44, it cannot dis-
tinguish between isoforms. This should also be the case
for the studies referred to as using an anti-CD44S anti-
body [14]. We used q-RT-PCR with exon-exon spanning
primers specific for CD44S, v2-v10, v3-v10 and v8-v10
to analyze a large set of breast cell lines and tumors.
We found a very heterogeneous expression pattern of
the CD44 isoforms in the different cell lines and interest-
ingly the basal B (also referred to as mesenchymal) cell
lines show a higher expression of CD44S compared to
basal A cell lines. Interestingly, a shift in splicing pattern
was observed when changing from adherent to mammo-
sphere culture and overall the expression of CD44S
decreased and the other isoforms increased their expres-
sion. This illustrates a plasticity of CD44 isoform expres-
sion possibly dependent on growth conditions, which
might be assigned to in vivo tumor growth as well.
In the patient material tumors containing cells of the
CD44
+/CD24
- phenotype were positively correlated to
all variants except for CD44S. Instead, tumors with a
strong positive staining for another CSC marker,
ALDH1, were associated with CD44S expression. We
found little overlap between tumors of CD44
+/CD24
-
and ALDH1 positive phenotype, which might indicate
that these different markers symbolizes CSCs of differ-
ent origin.
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Figure 4 Expression of alternatively spliced transcripts of CD44
in breast cancer tumors classified into molecular subtypes. A-E.
All isoforms except for the CD44 standard were differentially
expressed in the different molecular subtypes. The CD44v2-v10 and
CD44v3-v10 variants were highly expressed in luminal A tumors
whereas the CD44v8-v10 isoform was associated to basal- and
normal-like tumors. The CD44 standard variant had the highest
median expression in HER2-enriched tumors. The numbers of
tumors in each subtype are shown at top.
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Page 9 of 13Figure 5 Hierarchical clustering of breast tumors based on CD44 isoform expression resulted in four main clusters. The heatmap shows
relative mRNA expression levels (red, high; green, low). Tumors in Cluster C and D were associated to the basal-like molecular subtype and
cluster B was associated to luminal A-classified tumors. Cluster B and D had the highest proportions of tumors of the CD44+/CD24- phenotype.
Table 5 Associations of cluster A, B, C and D to clinical characteristics
All
n = 187(%)
Cluster A
n = 35 (%)
Cluster B
n = 46 (%)
Cluster C
n = 53(%)
Cluster D
n = 53(%)
P
1
Age 180 0.014
< 50 years 47 (26) 3(9) 9(20) 15(30) 20(38)
≥50 years 133 (74) 30(91) 36(80) 35(70) 32(62)
Tumor size 167 0.601
≤20 mm 46 (28) 11(33) 13(30) 13(28) 9(20)
> 20 mm 121 (72) 22(67) 30(70) 34(72) 35(80)
Lymph node status 166 0.161
Negative (n = 0) 52 (31) 8(24) 10(23) 15(32) 19(44)
Positive (n > 0) 114 (69) 25(76) 33(77) 32(68) 24(56)
S-phase fraction 119 0.001
Low (< 12%) 75 (63) 19(79) 25(86) 12(43) 19(50)
High (≥12%) 44 (37) 5(21) 4(14) 16(57) 19(50)
ER 180 0.009
Negative (< 25 fmol/mg) 86 (48) 12(34) 15(33) 32(62) 27(56)
Positive (≥25 fmol/mg) 94 (52) 23(66) 30(67) 20(38) 21(44)
PgR 178 0.023
Negative (< 25 fmol/mg) 107 (60) 16(48) 20(47) 38(73) 33(66)
Positive (≥25 fmol/mg) 71 (40) 17(52) 23(53) 14(27) 17(34)
HER2 82 0.012
Weak/negative 63 (77) 8(62) 24(92) 15(60) 16(89)
Strong (score = 3) 19 (23) 5(38) 2(8) 10(40) 2(11)
EGFR 69 0.188
Weak/negative 58 (84) 10(100) 15(79) 20(91) 13(72)
Strong (score≥7) 11 (16) 0(0) 4(21) 2(9) 5(28)
PTEN 110 0.511
Negative 34 (31) 5(26) 7(23) 12(40) 10(33)
Positive 76 (69) 14(74) 24(77) 18(60) 20(67)
PIK3CA 107 0.015
Wildtype 76 (71) 10(56) 16(55) 26(87) 24(80)
Mutation 31 (29) 8(44) 13(45) 4(13) 6(20)
Distant metastasis 149 0.269
Negative 99 (66) 22(67) 32(78) 23(59) 22(61)
Positive 50 (33) 11(33) 9(22) 16(51) 14(39)
Unsupervised hierarchical clustering using all four isoforms of CD44 was performed to obtain the different clusters.
1 Fisher’s exact test
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Page 10 of 13CD44 isoform expression data and unsupervised
hierarchical cluster analysis subdivided tumors into
four main groups with profoundly different isoform
expression patterns. The nonrandom occurrence of
tumors of particular phenotypes in the different clus-
ters suggests that CD44 may be part of the tumor pro-
gression program that drives development to distinct
molecular subtypes or, alternatively, a consequence of
this process. It has been suggested that alternative spli-
cing of CD44 is regulated by tissue-specific factors,
mitogenic signals, and cell differentiation [12].
Mesenchymal cells mostly splice out the variable
exons, which may explain the predominant expression
of CD44S in Cluster C tumors dominated by a basal-
like and more undifferentiated phenotype. Recently, a
high expression of CD44S has also been shown to be
essential for cells to undergo epithelial-to mesenchy-
mal transition [34]. On the other hand, steroid recep-
tor positive and mostly luminal tumors of Cluster A or
B, with more active growth factor receptor-RAS-
MAPK signaling, are more likely to retain the variable
exons of the CD44 precursor transcript. The variable
region encode the extracellular and membrane-proxi-
mal stem structure and a unique motif required for
addition of heparan sulphate is located in exon v3,
which is present in CD44v2-v10 and v3-v10 isoforms.
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Figure 6 Overall survival in patient subgroups derived from hierarchical clustering of CD44 isoform gene expression data. The 10-year
overall survival differed between the four clusters A-D (log rank P = 0.05). The number of patients at risk in each cluster is shown below the
time axis.
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Page 11 of 13It has also been suggested that various CD44 isoforms
function as co-receptors to growth factor receptor tyr-
osine kinases, and/or that CD44 molecules act as plat-
forms for matrix metalloproteinase activity and growth
factor precursor cleavage [12]. Our results may suggest
that EGFR signaling preferentially cooperates with
CD44v8-v10, while CD44S is more advantageous in
tumors with strong expression of HER2. However,
since we base our analysis on nucleic acid extracts
from homogenized tumor tissue, including a mixture
of tumor and stromal cells, we cannot exclude the pos-
sibility that the different patterns of CD44 isoforms are
influenced by the varying presence of infiltrating cells.
Moreover, our assumptions depend on CD44 tran-
scripts being translated and expressed as functional
protein molecules.
Nevertheless, since CD44 has been shown to be ampli-
fied and overexpressed in breast cancer, this implicates a
functional role in tumor development and growth [35].
Our results support this very well since we find associa-
tions between different CD44 splice variants and impor-
tant clinical markers such as HER2, ER and PgR and
also to different molecular subtypes and overall survival.
Since CD44 molecules can act as co-receptors, as well
as give rise to downstream signaling in many different
ways, our findings are of importance in future develop-
ment of therapy against CSCs.
Conclusions
Our results suggest that specific CD44 isoforms may
have distinct roles in different breast cancer subtypes
and can potentially be involved in specific oncogenic
signaling pathways. Attempts to link CD44 to CSCs and
tumor development should consider the expression of
various CD44 isoforms.
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